Cardiac Ultrasound Update: FDA Clears Software with 45 Automated Parameters for Echocardiographic Analysis
Strain imaging analysis is one of the automated parameters included in the newly FDA-cleared Us2.v2 software for adjunctive review of echocardiographic images.
In what may provide a boost for streamlining cardiac ultrasound workflows, the Food and Drug Administration (FDA) has granted 510(k) clearance for the Us2.v2 software (Us2.ai), which reportedly provides 45 automated parameters for adjunctive assessment of echocardiographic images.
Key aspects of the Us2.v2 software include strain imaging assessment, regional strain analysis, aortic stenosis measurement as well as analysis of left and right atrial and ventricular linear dimensions, according to Us2.ai.
The newly FDA-cleared Us2.v2 software reportedly provides 45 automated parameters for adjunctive assessment of echocardiographic images. (Image courtesy of Us2.ai.)
Emphasizing that the software’s real-time automated capabilities reduce the variability that can occur with human assessment, Us2.ai said the Us2.v2 software also enhances workflow with explainable artificial intelligence (AI) output and streamlined reporting.
“By offering advanced capabilities that significantly enhance both precision and efficiency of echocardiographic analysis, this innovation dramatically reduces analysis time thereby speeding up clinical workflow. This is particularly helpful in clinical states that require additional imaging parameters such as strain, or are challenged by variability in interpretation such as aortic stenosis, said Madhav Swaminathan, M.D., a past president of the American Society of Echocardiography (ASE) and an associate professor of anesthesiology at Duke University Medical Center in Durham, N.C.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
